Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00469495
Other study ID # 0701008939
Secondary ID
Status Completed
Phase N/A
First received May 2, 2007
Last updated August 25, 2009
Start date February 2007
Est. completion date November 2008

Study information

Verified date August 2009
Source Hospital Universitário Professor Edgard Santos
Contact n/a
Is FDA regulated No
Health authority Brazil: National Committee of Ethics in ResearchUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this project is to investigate the efficacy of early, empiric anti-helminthic therapy combined with standard pentavalent antimony in the treatment of subjects co-infected with helminths and cutaneous leishmaniasis caused by L. brasiliensis. The study hypothesis is that early intervention with antihelminthic therapy will improve response rates to antimony in subjects with cutaneous leishmaniasis.


Description:

Leishmaniases are a group of diseases caused by a parasite and transmitted by the sand fly. There are a number of diseases associated with infection ranging from simple skin lesions to a severe, fatal form. The standard treatment of cutaneous leishmaniasis (CL) is a 20 day course of antimony which, although fairly effective, has multiple side effects and is difficult to administer. The populations that are affected by leishmaniasis are usually also affected by intestinal helminths (worms). It is unknown what effect these two diseases have on each other and the immune system. As pathology in CL is mediated by an inflammatory reaction and helminths down regulate inflammation, helminthic infection may be beneficial for leishmaniasis. However, a recent study by our research group suggested that subjects infected with both leishmania and helminths have longer healing times and are less likely to respond to antimony. Since failure of initial therapy often results in repeat courses of the drug or development of more severe disease, we propose a study to investigate the role of early treatment for co-existing helminth infections in improving response rates to antimony in subjects with CL.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date November 2008
Est. primary completion date September 2008
Accepts healthy volunteers No
Gender Both
Age group 13 Years to 50 Years
Eligibility Inclusion Criteria:

- Subjects with a diagnosis of CL based on the presence of typical skin lesions and a positive Montenegro skin test

- Evidence of helminthic infection by parasitological examination of first stool sample

- Males or females between 13 and 50 years of age

- Maximum of 3 ulcers with no more than 2 body regions involved

- Period of 15 to 60 days from the onset of the first ulcer

- Subject agreement to follow-up visits and therapy

- Ability to give informed consent

Exclusion Criteria:

- Pregnancy

- Breastfeeding mothers

- Presence of mucosal disease

- History of prior treatment with antimonial drugs.

- History of prior treatment with anthelminthic drugs within the last 6 months.

- History of allergy to pentavalent antimony or antihelminthic

- Presence of underlying disease which affects the immune response, such as HIV and diabetes mellitus

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Anti-helminthic

meglumine antimony


Locations

Country Name City State
Brazil Posto de Saude de Corte de Pedra Salvador Bahia

Sponsors (1)

Lead Sponsor Collaborator
Hospital Universitário Professor Edgard Santos

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bidirectional measurements will be taken of the subjects' lesions at each visit and will be categorized as active or healed by a dermatologist. 90 days
See also
  Status Clinical Trial Phase
Completed NCT04041453 - Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients Phase 2
Active, not recruiting NCT03014167 - Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Phase 3
Completed NCT02385058 - Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Phase 4
Withdrawn NCT02636803 - Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults Phase 2
Completed NCT02725255 - Design and Clinical Evaluation of a School Meal With Deworming Properties Phase 2/Phase 3
Active, not recruiting NCT04227834 - Soil-transmitted Helminth Reinfection Rates After Single and Repeated School Hygiene Education N/A
Completed NCT03173742 - Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil) Phase 1
Completed NCT02397772 - Impact of Alternative Treatment Strategies and Delivery Systems for Soil-transmitted Helminths in Kenya Phase 4
Completed NCT00130910 - Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation N/A
Completed NCT00004996 - Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections
Recruiting NCT00001230 - Host Response to Infection and Treatment in Filarial Diseases
Completed NCT04041427 - Urine Albendazole Levels for Coverage Assessment N/A
Completed NCT02396407 - Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health N/A
Terminated NCT01271049 - An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths N/A
Terminated NCT00817713 - Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa? N/A
Completed NCT02362932 - The Effect of an Urban Sanitation Intervention on Child Health N/A
Completed NCT02420574 - Assessment of Drug Efficacy of Local Albendazole N/A
Completed NCT00507221 - Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression N/A
Recruiting NCT01459146 - Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Phase 4
Recruiting NCT01308268 - Management of Soil-transmitted Helminthiasis and Strongyloidiasis N/A